{"id":"W2766103705","doi":"10.1007/s41669-018-0112-1","title":"Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McGill University","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Pembrolizumab; Regimen; Internal medicine; Oncology; Progression-free survival; Cost effectiveness; Immunotherapy; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002662743,0.0001444538,0.0003724592,0.00007040766,0.00003021802,0.00001619638,0.0001466722,0.00002720316,0.0007500999],"category_scores_gemma":[0.000005731268,0.0001322627,0.00004619176,0.00003809637,0.00001350775,0.0002279716,0.00002770875,0.00003680282,0.00001283041],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006962179,"about_ca_system_score_gemma":0.003071001,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.4475948,"about_ca_topic_score_gemma":0.6351725,"domain_scores_codex":[0.9990692,0.00002681521,0.0003760255,0.0002688596,0.0000979092,0.0001612029],"domain_scores_gemma":[0.9993241,0.0000711914,0.0002495631,0.0002071138,0.00009636454,0.00005169511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.09628028,0.001545083,0.4573766,0.0002598274,0.001539133,0.000002094671,0.0007920453,0.03975776,0.0009253995,0.0001890993,0.001057064,0.4002756],"study_design_scores_gemma":[0.4766383,0.009059108,0.2624628,0.0002862927,0.0007046829,0.000006469616,0.0004823607,0.1969949,0.02438547,0.0002858441,0.02788225,0.0008114814],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992232,0.0001220569,0.000002220145,0.0004613411,0.0003543313,0.004900373,0.0001398477,0.000003932716,0.001783845],"genre_scores_gemma":[0.9985167,0.0001506462,0.00008926621,0.0002595723,0.0000180775,0.0003542902,0.0003466203,0.00002431889,0.0002404659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3994642,"threshold_uncertainty_score":0.9968499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02394847874053593,"score_gpt":0.3310521936035749,"score_spread":0.3071037148630389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}